Durvalumab Plus Chemoradiotherapy Does Not Extend PFS in Locally Advanced Cervical Cancer
March 28th 2022The phase 3 CALLA study did not achieve its key end point of progression-free survival improvement with the addition of durvalumab to chemoradiotherapy in patients with locally advanced cervical cancer.
Read More
Atezolizumab Plus Chemoradiation Is Safe in Node+, Locally Advanced Cervical Cancer
March 23rd 2022Findings presented during the SGO Annual Meeting show that atezolizumab given prior to concurrent chemoradiation may be safe with immune modulating activity in patients with node-positive, locally advanced cervical cancer.
Read More
Immunotherapy Shakes Up Cervical Cancer Treatment Paradigm
February 17th 2022In an interview with Lt Col Yovanni Casablanca, MD, discussed the incorporation of new treatments into the cervical cancer paradigm and provided insight into the necessity of inclusive research with novel therapies.
Read More
Cemiplimab FDA Approval Application for Recurrent or Metastatic Cervical Cancer Withdrawn
January 28th 2022Ahead of its Prescription Drug User Fee Act target action date, the supplemental biologics license application for cemiplimab as treatment of metastatic cervical cancer has been withdrawn.
Read More
Immunotherapy Sparks Excitement for New Cervical Cancer Treatments
January 25th 2022Immunotherapy has especially demonstrated broad activity in cervical cancer, fueling development in this area and providing further signs of hope for new treatment options to come into the landscape with greater efficacy and manageable safety profiles.
Read More
Cervical Cancer Awareness Month: Trials Assess New Immunotherapies
January 19th 2022Margarett C. Ellison, MD, MHA, FACS, FACOG, gynecologic oncologist for Gynecologic Oncology of Tallahassee, a Division of Florida Cancer Specialists, reviews potential immunotherapy treatments for Cervical Cancer Awareness Month.
Read More
PR-Driven Approaches to Treating Granulosa Cell Tumors
October 16th 2021Even though most early stage adult patients with granulosa cell tumors experience an excellent outcome, up to 33% of patients will eventually develop a tumor relapse. Recurrence may be detected many years after the initial treatment, thus prolonged surveillance is necessary.
Read More